miR-34C Disrupts the Stemness of Purified CD133+ Prostatic Cancer Stem Cells

被引:8
|
作者
Chen, Yuan
Rao, Qun
Zhang, Huiping
Xu, Hua
Zhang, Cuntai
Zhuang, Qianyuan
Ye, Zhangqun [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Urol, Wuhan 430030, Peoples R China
关键词
ANDROGEN RECEPTOR; THERAPY; IDENTIFICATION; EXPRESSION; RESISTANCE; MICRORNA; PROMOTES;
D O I
10.1016/j.urology.2016.07.021
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To find the potential micro-RNA (miRNA) that could determine the fate of prostate cancer stem cells. MATERIALS AND METHODS We compared miRNA expression between our purified CD133(+) prostatic cancer stem cells (PCSCs) and CD133-cells. Sphere formation assay and matrigel-based cell invasion assay were applied to determine the stemness of CD133(+) PCSCs after our manipulation of miRNA using miRNA mimic or miRNA inhibitor. RESULTS In this study, we identified that miR-34C was under-expressed in the purified CD133(+) PCSCs and enforced introduction of miR-34C attenuated the stemness of CD133(+) PCSCs. Clinically, we also observed a negative correlation between miR-34C and CD133. CONCLUSION Our data strongly suggest that miR-34C may play essential role in conferring castration resistance by equilibrating PSCS population. (C) 2016 Elsevier Inc.
引用
收藏
页码:177.e1 / 177.e9
页数:9
相关论文
共 50 条
  • [1] CD133+ and CD133- Cancer stem cells in glioblastoma
    Beier, D.
    Hau, P.
    Proescholdt, M.
    Lohmeier, A.
    Aigner, L.
    Brawanski, A.
    Bogdahn, U.
    Beier, C. P.
    NEURO-ONCOLOGY, 2006, 8 (04) : 317 - 317
  • [2] CD133+ cancer stem cells in lung cancer
    Wang, Shuang
    Xu, Zhen Ye
    Wang, Li Fang
    Su, Wan
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2013, 18 : 447 - 453
  • [3] The Role of Cancer Stem Cells (CD133+) in Malignant Gliomas
    Cho, Der-Yang
    Lin, Shinn-Zong
    Yang, Wen-Kuang
    Hsu, Den-Mei
    Lin, Hung-Lin
    Lee, Han-Chung
    Lee, Wen-Yeun
    Chiu, Shao-Chih
    CELL TRANSPLANTATION, 2011, 20 (01) : 121 - 125
  • [4] Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
    Yang Jing-pu
    Liu Yan
    Zhong Wei
    Yu Dan
    Wen Lian-ji
    Jin Chun-shun
    CHINESE MEDICAL JOURNAL, 2011, 124 (07) : 1055 - 1060
  • [5] Chemoresistance of CD133+ cancer stem cells in laryngeal carcinoma
    YANG Jingpu
    LIU Yan
    ZHONG Wei
    YU Dan
    WEN Lianji
    JIN Chunshun
    中华医学杂志(英文版), 2011, (07) : 1055 - 1060
  • [6] CHARACTERIZATION AND IMAGING OF CD133+ LIVER CANCER STEM CELLS
    Suetsugu, A.
    Osawa, Y.
    Aoki, H.
    Kunisada, T.
    Tsurumi, H.
    Hoffman, R. M.
    Moriwaki, H.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S445 - S446
  • [7] DIFFERENTIAL NUMBER OF CD34+, CD133+ AND CD34+/CD133+ CELLS IN PERIPHERAL BLOOD OF PATIENTS WITH CONGESTIVE HEART FAILURE
    Fritzenwanger, M.
    Lorenz, F.
    Jung, C.
    Fabris, M.
    Thude, H.
    Barz, D.
    Figulla, H. R.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2009, 14 (03) : 113 - 117
  • [8] Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells
    Suetsugi, Atsushi
    Nagaki, Masahito
    Aoki, Hitomi
    Motohashi, Tsutomu
    Kunisada, Takahiro
    Moriwaki, Hisataka
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (04) : 820 - 824
  • [9] Differential number of CD34+, CD133+ and CD34+/CD133+ cells in peripheral blood of patients with congestive heart failure
    M Fritzenwanger
    F Lorenz
    C Jung
    M Fabris
    H Thude
    D Barz
    HR Figulla
    European Journal of Medical Research, 14 (3)
  • [10] MIR-34C REGULATES THE PROLIFERATION AND APOPTOSIS OF LUNG CANCER CELLS
    Jiang, Xianliang
    Li, Ming
    Kei, Li
    CLINICAL AND INVESTIGATIVE MEDICINE, 2020, 43 (04): : E56 - E62